Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Depression in Parkinson's disease.

Theresa A Zesiewicz1, Robert A Hauser

  • 1Parkinson's Disease and Movement Disorders Center, University of South Florida College of Medicine, 4 Columbia Drive, Suite 410, Tampa, FL 33606, USA. tzesiewi@hsc.usf.edu

Current Psychiatry Reports
|January 30, 2002
PubMed
Summary

Depression frequently affects Parkinson's disease (PD) patients, impacting quality of life. This review covers PD depression epidemiology, treatments, and drug interactions to guide clinical care.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A double-blind, randomized, multicenter, phase 2b study of the safety and efficacy of suvecaltamide in essential tremor.

Parkinsonism & related disorders·2026
Same author

Impact of COVID-19 on Movement Disorders Patients in the Outpatient Setting.

Cureus·2026
Same author

Real-World Safety and Effectiveness of 24-Hour Foslevodopa/Foscarbidopa in Parkinson's Disease: ROSSINI Study 6-Month Interim Results.

Neurology and therapy·2026
Same author

Tavapadon as Adjunctive Treatment for Parkinson Disease: The TEMPO-3 Randomized Clinical Trial.

JAMA neurology·2026
Same author

DaxibotulinumtoxinA for Injection in Adults with Cervical Dystonia: Clinical Insights from a Real-World Early Experience Program.

Movement disorders clinical practice·2026
Same author

LRRK2 as a Potential Disease-Modifying Target in Sporadic Parkinson's Disease.

Movement disorders : official journal of the Movement Disorder Society·2025

Area of Science:

  • Neurology
  • Psychiatry
  • Clinical Pharmacology

Background:

  • Depression is a common and impactful comorbidity in Parkinson's disease (PD).
  • Effective management of depression is crucial for improving the quality of life for PD patients.
  • Gaps in understanding PD depression's epidemiology and optimal treatment persist.

Purpose of the Study:

  • To summarize the current epidemiology of depression in Parkinson's disease.
  • To review available treatment options for depression in PD patients.
  • To discuss potential interactions between antidepressants and other medications used in PD management.

Main Methods:

  • Literature review of epidemiological studies on depression in PD.
  • Synthesis of clinical trial data and expert guidelines on PD depression treatment.
  • Analysis of pharmacological data regarding antidepressant-PD medication interactions.

Main Results:

  • Depression is highly prevalent in Parkinson's disease populations.
  • Various antidepressant classes are available, with selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) often considered.
  • Potential interactions exist between certain antidepressants and PD medications, requiring careful clinical consideration.

Conclusions:

  • Accurate identification and management of depression are essential components of holistic Parkinson's disease care.
  • Treatment selection should consider efficacy, side effect profiles, and potential drug interactions.
  • Further research is needed to optimize depression treatment strategies and understand underlying mechanisms in PD.

Related Experiment Videos